Vasculitis & polymyalgia rheumatica
Secukinumab is effective and safe for patients with giant cell arteritis after tocilizumab failure
Authors' conclusion
Secukinumab demonstrated effectiveness in achieving clinical and imaging remission in patients with GCA failing tocilizumab.
Study context
- Population
- Patients with GCA with inadequate response to tocilizumab (relapse on clinical symptoms and/or imaging), three centres in Italy; all women, median age 72 years (IQR, 67–73)all women
- Participants
- 6 patients
- Outcome
- Clinical response: resolution of symptoms and normalization of inflammatory markers; imaging to confirm remission where it had documented relapse
- Follow-up
- Six months
Methodological detailsmulticentre, real-world
- Multicentre
- Real-world
Main finding
As reported in the abstract
Clinical and laboratory remission · within six months
All patients achieved clinical and laboratory remission
6
Imaging confirmed complete resolution of vasculitis in patients with documented active disease before secukinumab
4
Observational data: associations, not effects.
Further findings
Imaging: complete resolution of vasculitis in patients with documented active disease before secukinumab
- Complete resolution of vasculitis on imaging
- 4
Time to tocilizumab failure (before secukinumab)
- Median time to tocilizumab failure (IQR 11-22)
- 14 months
GC discontinuation · within four months
- Successfully discontinued GC
- 3
- Continued low-dose prednisone (1.25, 2.5, 5 mg daily)
- 3
Safety
| Outcome | Values |
|---|---|
| Adverse events during secukinumab treatment | Secukinumab 0 events |
Adverse events during secukinumab treatment
- No adverse events reported
Original publication
Secukinumab is effective and safe for patients with giant cell arteritis after tocilizumab failure. Rheumatology (Oxford). Published 14 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →